Actively Recruiting
Phase 1 Study of JADE201 Given by Injection to Adults With Rheumatoid Arthritis Randomized, Double-Blind, Placebo-Controlled Single Dose Safety and Effect Study
Led by Jade Biosciences, Inc. · Updated on 2026-06-01
36
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting a Phase 1, first-in-human study to evaluate JADE201 in adults with Rheumatoid Arthritis RA. The study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of JADE201 compared to placebo. This trial is randomized, double-blind, and placebo-controlled, involving about 36 participants to support future development in autoimmune conditions. Participants will receive a single subcutaneous injection of either JADE201 or a matching placebo. The study includes multiple cohorts with ascending doses to observe how the drug behaves in the body and its effects. This approach helps researchers understand the safety and dosing before moving on to larger trials. During the trial, participants will stay as inpatients for scheduled visits and treatment, undergoing various laboratory tests and study procedures. Researchers will monitor safety and tolerability from the day of dosing through 36 weeks. They will also measure drug concentration and behavior in the body at multiple time points. Participants must comply with contraceptive and lifestyle requirements and will be followed closely throughout the study period.
CONDITIONS
Brief Title
A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
Research Team
J
Jade201 Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
